Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
Instagram Outage Disrupts Thousands of U.S. Users 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
CAMBRIDGE, Md., Sept. 18, 2017 -- ConverGene is pleased to announce that it has entered into a collaboration with The University of Texas MD Anderson Cancer Center (“MD Anderson”) to characterize ConverGene’s first-in-class dual inhibitor of BET bromodomains and dopamine receptor 2, in ovarian carcinoma. Work will be done under the guidance of Dr. Sherry Wu in the laboratory of Dr. Anil Sood. The program will advance in 2 distinct phases. First the unique mechanism of action of the ConverGene lead compound will be assessed in vitro then clinically relevant activity will be determined utilizing in vivo model systems developed in the Sood lab.
Dr. Jeff Strovel, PhD, President and CEO of ConverGene, commented, “We are very excited to kickoff this study with MD Anderson. Our first-in-class cancer drug candidates will be evaluated by a world-class team working with a renown leader in the field of gynecological cancer.”
Dr. Anil Sood is Professor and Vice Chair for Translational Research in the Departments of Gynecologic Oncology and Cancer Biology at the MD Anderson Cancer Center. He is also Director of the multi-disciplinary Blanton-Davis Ovarian Cancer Research Program. Dr. Sood co-leads the Ovarian Cancer Moonshot Program.
NOTES TO EDITORS
About ConverGene
ConverGene (www.convergenepharma.com) is a small molecule discovery company leveraging rational drug design. Our mission is to develop therapeutics with novel mechanisms of action for patients with limited or no treatment options.
Our first-in-class lead drug program, CVG-101, contains small molecule inhibitors formulated for oral administration that are selective against BET proteins. CVG-101 contains multiple clinical candidates that exhibit dual activity, simultaneously inhibiting epigenetic processes within cancer cells as well as D2R which is a driver of proliferation and metastasis in cancer. We predict this drug will gain broad clinical usage due to its dual activity and potential to reduce the development of resistance.
ConverGene believes that its portfolio of intellectual property protects its product candidates and technologies. Opportunities to realize significant early value inflection points are available through strategic licensing of our drug candidates. For additional information on ConverGene, please visit its website at convergenepharma.com.
For more information please contact Dr. Elizabeth Smith, [email protected]
